No Picture
Uncategorized

CEO Interview EXPRESS

CEO’s: Share your company’s growth story with Wall Street Reporter’s global investor audience. Our new “Express” format is fully automated, and you can do this interview anytime, right from your computer or smart phone. CLICK […]

Spotlight Stocks

Enthusiast Gaming (NASDAQ: EGLX) (TSE: EGLX) CEO Adrian Montgomery: “The Home for Gen Z and Millennial Video Game and Esports Fans”

Enthusiast Gaming Holdings Inc. (NASDAQ: ENGMF) Q4 2020 Earnings Highlights “…Enthusiastic Gaming is the home for Gen Z and millennial video game and esports fans. We build communities for these fans that are powered by […]

Uncategorized

Novant Health Initiates Phase 2b/3 Trial with CytoDyn’s (OTC: CYDY) Leronlimab for Severely and Critically Ill COVID-19 Patients

FDA has approved 54 Emergency INDs to allow access to leronlimab for severely and critically ill COVID-19 patients VANCOUVER, Washington and WINSTON-SALEM, May 07, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a […]

Uncategorized

CytoDyn’s (OTC: CYDY) Phase 2 Basket Trial for 22 Solid Cancer Tumors Treats First Patient with Leronlimab; Patient Enrollment Delayed Due to COVID-19

VANCOUVER, Washington, April 15, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has […]

Uncategorized

CytoDyn Signs Letter of Intent for the Joint Development and Licensing of Leronlimab in China with Longen China Group

VANCOUVER, Washington, Feb 12, 2020 (GLOBE NEWSWIRE via COMTEX) — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, […]

Uncategorized

Next Super Stock Investor Conference September 26, 2019

September 26, 2019 conference presenters:     Hoth Therapeutics, Inc. (NASDAQ: HOTH) CEO Robb Knie, shares the latest updates on Hoth’s pipeline of targeted dermatological therapies, which address multi-billion dollar market opportunities, including: eczema, psoriasis, chronic wound […]